WW (WW) Q2 2026 Earnings Call Transcript
WeightWatchers (WW) reported Q2 2026 revenue of $162.3 million, down 14.2% year over year, with behavioral revenue falling 22.7% to $121.5 million. Clinical end-of-period subscribers rose 55.7% to 197,000 and total subscribers fell to 2.5 million. Adjusted EBITDA was $39.8 million. 2026 guidance: revenue $620-$635 million, adjusted EBITDA $105-$115 million.
How this was made
The 30-second read
Why it matters
The call combines financial performance (revenue, EBITDA margin, cash flow), balance-sheet progress (term loan principal reduction and prepayments), and commercial/distribution catalysts (Sam’s Club collaboration, Libby access, Medicare GLP-1 bridge coverage through late 2027).
Market read
Traders can update models using the reaffirmed 2026 revenue and adjusted EBITDA ranges, Q2 subscriber mix and margin/cash flow metrics, and the timing commentary on marketing spend (lowest in Q3, ramp in Q4).
What to watch
Management notes Q3 is the lowest marketing-spend quarter and that growth includes moderate declines in clinical subscribers in remaining quarters, which could pressure subscriber trends into late 2026.
Background
WW is in a multiyear transformation shifting subscribers from legacy behavioral tiers toward clinical and higher-value Core+ offerings, supported by GLP-1-related programs.
Ticker impact
WW reported Q2 2026 results and reaffirmed 2026 revenue guidance of $620M to $635M, alongside clinical and Core+ subscriber growth.
Near-term bias modestly positive if investors focus on reaffirmed guidance, margin stability, and debt reduction; downside risk if behavioral subscriber declines re-accelerate.
The article provides multiple decision-useful datapoints: Q2 revenue decline, subscriber mix shifts, adjusted EBITDA margin improvement, operating cash flow, and reaffirmed full-year guidance, plus a new distribution and Medicare GLP-1 bridge channel.
Market effects
Reinforces the weight-loss subscription model shift toward GLP-1-supported clinical tiers, which may influence sentiment around obesity-care platforms and retention economics.
Primarily US-focused given Sam’s Club collaboration and Medicare GLP-1 bridge program details.
Limited direct global impact in the provided text, as the distribution and Medicare program are US-centric.
Counterpoint
The clinical mix improvement may be partially offset by lapping prior GLP-1 contributions and continued declines in behavioral subscribers, so the revenue decline could persist despite ARPU gains.
Key entities
- public_companyWW International, Inc.
Reported Q2 2026 results, reaffirmed 2026 guidance, and outlined subscriber mix shift plus new distribution and Medicare GLP-1 bridge program access.
- partnerSam's Club
Announced strategic collaboration to bring the WeightWatchers brand to its membership base.
- platform_partnerLibby
Digital platform/channel through which members can access WeightWatchers Med+.
